Passkey Therapeutics
Cambridge, Massachusetts, United States · Biotechnology, Health Care, Therapeutics · 50 employees
Passkey Therapeutics is pioneering a new class of medicines, Synergistic Multifunctional Therapeutics or SMThs, designed to address complex diseases by targeting rare combinations of proteins that work together. Using its proprietary Locksmith platform, the company is advancing programs across multiple therapeutic areas to create new options for patients with common, hard-to-treat conditions.
Funding history
- Series seed — $20.0M — Oct 2024
Recent signals
- May 19, 2026: Passkey Therapeutics Appoints Mandeep Kaur as Chief Medical Officer
- Oct 22, 2024: Launched Passkey Therapeutics Launches Innovative SMThs Platform to Transform Drug Discovery with $20 Million Funding.
- Oct 22, 2024: Raised $20.0M in Series seed
See plans & pricing → Track Passkey Therapeutics’s funding, hiring, and signals — with verified contacts — on Fundz.